Clinical Trials Browser

Withdrawn × atezolizumab × Thoracic × Clear all

NCT06713798 2026-03-23

INDIGO

Phase 2 Withdrawn

Lung Neoplasms

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05007769 2021-11-05

RAN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04611776 2021-06-16

CATHAYA

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03786419 2021-05-13

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Phase 2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Thoracic Neoplasms

NCT04267237 2021-02-04

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03498222 2020-02-25

iTRAP

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02495636 2017-06-22

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung